These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Palmer AJ, Tucker DM. Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888 [Abstract] [Full Text] [Related]
4. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Eddy DM, Schlessinger L, Kahn R. Ann Intern Med; 2005 Aug 16; 143(4):251-64. PubMed ID: 16103469 [Abstract] [Full Text] [Related]
5. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA. Diabet Med; 2004 Nov 16; 21(11):1229-36. PubMed ID: 15498090 [Abstract] [Full Text] [Related]
6. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM, Diabetes Prevention Program Research Group. Diabetes Care; 2003 Jan 16; 26(1):36-47. PubMed ID: 12502656 [Abstract] [Full Text] [Related]
12. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM. Health Technol Assess; 2004 May 16; 8(21):iii-iv, 1-182. PubMed ID: 15147610 [Abstract] [Full Text] [Related]
14. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective. Neeser K, Lübben G, Siebert U, Schramm W. Pharmacoeconomics; 2004 May 16; 22(5):321-41. PubMed ID: 15061682 [Abstract] [Full Text] [Related]
15. Cost saving analysis of prediabetes intervention modalities in comparison with inaction using Markov state transition model-A multiregional case study. Al-Omar HA, Czech M, Quang Nam T, Gottwald-Hostalek U, Vesic N, Whitehouse J, Dawson M. J Diabetes; 2024 May 16; 16(5):e13553. PubMed ID: 38664882 [Abstract] [Full Text] [Related]
16. Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. Olchanski N, van Klaveren D, Cohen JT, Wong JB, Ruthazer R, Kent DM. Acta Diabetol; 2021 Jun 16; 58(6):707-722. PubMed ID: 33517494 [Abstract] [Full Text] [Related]
18. Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India. Islek D, Weber MB, Ranjit Mohan A, Mohan V, Staimez LR, Harish R, Narayan KMV, Laxy M, Ali MK. JAMA Netw Open; 2020 Jul 01; 3(7):e207539. PubMed ID: 32725244 [Abstract] [Full Text] [Related]
20. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Prevention Program Research GroupDiabetes Prevention Program Coordinating Center. dppmail@biostat.bsc.gwu.edu. Diabetes Care; 2012 Apr 01; 35(4):723-30. PubMed ID: 22442395 [Abstract] [Full Text] [Related] Page: [Next] [New Search]